Pfizer, Trump and tariffs Bourla

Pfizer's CEO says he's got a plan to deal with Trump's tariffs — move overseas drug manufacturing to the US
"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's election victory.
Pfizer could shift overseas production to US if Trump's pharma tariffs take hold, CEO says
As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert Bourla, Ph.D., outlined one potential response by his company if pharmaceut | Pfizer’s local manufacturing setup is already well positioned in the U.
Pfizer CEO says he's prepared to shift manufacturing to the U.S. amid tariff threats
CEO Albert Bourla said on Monday that the drugmaker could move some of its overseas manufacturing to its U.S. plants if necessary, as the Trump administration considers imposing tariffs on pharmaceuticals.
Pfizer could use existing US manufacturing to counter potential tariff hit
By Christy Santhosh (Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the United States, if required, as the Trump administration threatens numerous tariffs on imported goods.
Pfizer may soon move its overseas manufacturing to United States to counter potential tariff hit
Pfizer CEO Albert Bourla on Monday said that the company might move overseas manufacturing to its existing plants in the United States. The plan comes as the Trump administration
Pfizer's Strategic Manufacturing Shift Amidst Tariff Threats
Pfizer CEO Albert Bourla announced the possibility of shifting overseas manufacturing to U.S. plants. This response is due to the Trump administration's tariff threats on imported goods. Bourla mentioned their U.
Pfizer could move outside manufacturing to the US, says CEO
(Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the U.S., if required, as the Donald Trump administration threatens numerous tariffs on imported goods.
Pfizer comments on Q1, Q2 numbers amid higher rebate expense
Says “I don’t think the Street” has adjusted yet and that “they should have a look on it.” The company says the rebates that Pfizer (PFE) will ...
Trump Introducing Pfizer CEO Sparks Loud Booing Inside White House
A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...
FiercePharma10d
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
3 Things You Need to Know If You Buy Pfizer Today
We can refer to full-year 2019 revenue of about $51 billion and the company's comments about potential revenue of more than ...
Investing10h
Pfizer considers moving overseas production to U.S. amid tariff threats
Albert Bourla, the CEO of Pfizer, stated that the company is prepared to move its overseas manufacturing to the U.S. if ...
Pfizer: What The Summit Therapeutics Deal Brings
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
Pfizer Inc. stock rises Friday, still underperforms market
Shares of Pfizer Inc. PFE advanced 1.26% to $26.43 Friday, on what proved to be an all-around favorable trading session for ...
Hosted on MSN14h
Pfizer says more drugs can be made in its US plants for domestic market, if needed
Pfizer CEO Albert Bourla said on Monday that the drugmaker can shift manufacturing for the US market to its existing plants in the US, as the threat of tariffs puts a question mark over global supply ...